Vector Introduces Investigational Microneedle Technology for Peptide Delivery

PUBT · 1d ago
Vector Introduces Investigational Microneedle Technology for Peptide Delivery
  • Vector Science and Therapeutics introduced an investigational dissolving microneedle platform on Oct. 22, 2026, targeting peptide delivery through the skin.
  • The technology uses therapeutic peptides as the needles’ main structural component, with an initial focus on sports medicine and regenerative medicine.
  • Planned testing will assess needle strength, peptide stability and delivery performance, alongside manufacturing scalability.
  • The platform has no regulatory approval; safety, clinical efficacy and commercial viability remain unestablished.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vector Science and Therapeutics Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA78613) on October 22, 2026, and is solely responsible for the information contained therein.